GeneDx (WGS) Revenue & Revenue Breakdown
GeneDx Revenue Highlights
Latest Revenue (Y)
$305.45M
Latest Revenue (Q)
$116.74M
Main Segment (Y)
Diagnostic Test
Main Geography (Y)
Other
GeneDx Revenue by Period
GeneDx Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $305.45M | 50.79% |
| 2023-12-31 | $202.57M | -13.69% |
| 2022-12-31 | $234.69M | 10.60% |
| 2021-12-31 | $212.19M | 18.33% |
| 2020-12-31 | $179.32M | -8.59% |
| 2019-12-31 | $196.17M | - |
GeneDx generated $305.45M in revenue during NA 2024, up 50.79% compared to the previous quarter, and up 155.70% compared to the same period a year ago.
GeneDx Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | $116.74M | 13.68% |
| 2025-06-30 | $102.69M | 17.88% |
| 2025-03-31 | $87.11M | -8.91% |
| 2024-12-31 | $95.64M | 24.41% |
| 2024-09-30 | $76.87M | 9.02% |
| 2024-06-30 | $70.51M | 12.96% |
| 2024-03-31 | $62.42M | 8.72% |
| 2023-12-31 | $57.42M | 7.72% |
| 2023-09-30 | $53.30M | 9.44% |
| 2023-06-30 | $48.71M | 12.90% |
| 2023-03-31 | $43.14M | -29.68% |
| 2022-12-31 | $61.35M | -26.29% |
| 2022-09-30 | $83.23M | 130.13% |
| 2022-06-30 | $36.17M | -32.95% |
| 2022-03-31 | $53.94M | -6.68% |
| 2021-12-31 | $57.80M | 33.87% |
| 2021-09-30 | $43.18M | -7.87% |
| 2021-06-30 | $46.87M | -27.00% |
| 2021-03-31 | $64.20M | 0.38% |
| 2020-12-31 | $63.96M | 65.66% |
| 2020-09-30 | $38.61M | - |
GeneDx generated $116.74M in revenue during Q3 2025, up 13.68% compared to the previous quarter, and up 165.56% compared to the same period a year ago.
GeneDx Revenue Breakdown
GeneDx Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 | Dec 22 |
|---|---|---|
| Diagnostic Test, Institutional Customers | $65.11M | - |
| Diagnostic Test, Self Pay | $2.34M | - |
| Diagnostic Test, Third Party Insurance | $234.70M | - |
| Product and Service, Other | $3.29M | $7.36M |
| Diagnostic Test | $302.16M | $227.33M |
GeneDx's latest annual revenue breakdown by segment (product or service), as of Dec 24: Diagnostic Test (49.73%), Diagnostic Test, Third Party Insurance (38.63%), Diagnostic Test, Institutional Customers (10.72%), Product and Service, Other (0.54%), and Diagnostic Test, Self Pay (0.39%).
Quarterly Revenue by Product
| Product/Service | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 |
|---|---|---|---|---|---|---|
| Diagnostic Test, Third Party Insurance | $95.02M | $81.10M | $68.06M | $123.10M | $59.54M | $52.05M |
| Diagnostic Test | $113.52M | $99.82M | $85.76M | $155.30M | $77.42M | $69.44M |
| Diagnostic Test, Institutional Customers | $17.87M | $18.38M | $17.60M | $31.00M | $17.41M | $16.70M |
| Diagnostic Test, Self Pay | $629.00K | $339.00K | $96.00K | $1.19M | $460.00K | $692.00K |
| Product and Service, Other | $3.22M | $2.87M | $1.36M | $2.76M | $-544.00K | $1.07M |
GeneDx's latest quarterly revenue breakdown by segment (product or service), as of Sep 25: Diagnostic Test (49.30%), Diagnostic Test, Third Party Insurance (41.27%), Diagnostic Test, Institutional Customers (7.76%), Product and Service, Other (1.40%), and Diagnostic Test, Self Pay (0.27%).
GeneDx Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 24 |
|---|---|
| Other | $3.16M |
GeneDx's latest annual revenue breakdown by geography, as of Dec 24: Other (100.00%).
GeneDx Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ALHC | Alignment Healthcare | $2.70B | $1.02B |
| PRVA | Privia Health Group | $1.74B | $521.15M |
| ITGR | Integer | $1.72B | $467.69M |
| AAPG | Ascentage Pharma Group | $980.65M | $141.22K |
| ACAD | ACADIA Pharmaceuticals | $957.80M | $264.57M |
| TMDX | TransMedics Group | $441.54M | $157.37M |
| HNGE | Hinge Health | $390.40M | $123.83M |
| WGS | GeneDx | $305.45M | $116.74M |
| LGND | Ligand Pharmaceuticals | $167.13M | $47.63M |
| HTFL | Heartflow | $125.81M | $43.42M |
| NVST | Envista | - | $682.10M |